Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
PharmAthene to present its biological/ chemical weapons countermeasure program data at the HHS PHEMCE workshop

PharmAthene to present its biological/ chemical weapons countermeasure program data at the HHS PHEMCE workshop

DiaMedica to acquire all issued and outstanding shares of Sanomune

DiaMedica to acquire all issued and outstanding shares of Sanomune

CT imaging combined with Avastin may predict overall survival in metastatic colorectal cancer

CT imaging combined with Avastin may predict overall survival in metastatic colorectal cancer

Data from brentuximab vedotin and dacetuzumab programs to be presented by Seattle Genetics

Data from brentuximab vedotin and dacetuzumab programs to be presented by Seattle Genetics

Canadians with hemophilia A can use new treatment option, XYNTHA

Canadians with hemophilia A can use new treatment option, XYNTHA

MRI pioneer honored with MRC Millennium Medal

MRI pioneer honored with MRC Millennium Medal

MAbs for early detection of cancer

MAbs for early detection of cancer

Aegis Therapeutics signs License Agreement with Roche

Aegis Therapeutics signs License Agreement with Roche

iCo Therapeutics reports financial results for three months ended September 30, 2009

iCo Therapeutics reports financial results for three months ended September 30, 2009

Erbitux drug can reverse rare stomach disorder, report researchers

Erbitux drug can reverse rare stomach disorder, report researchers

EMEA grants orphan drug status for LFB Biotechnologies' recombinant anti-CD20 monoclonal antibody

EMEA grants orphan drug status for LFB Biotechnologies' recombinant anti-CD20 monoclonal antibody

Fourth-quarter and full year fiscal 2009 results announced by AVANIR Pharmaceuticals

Fourth-quarter and full year fiscal 2009 results announced by AVANIR Pharmaceuticals

Studies demonstrate clinical utility of Given Imaging's PillCam SB capsule endoscopy

Studies demonstrate clinical utility of Given Imaging's PillCam SB capsule endoscopy

Seattle Genetics and Agensys expand ADC collaboration

Seattle Genetics and Agensys expand ADC collaboration

PX’Therapeutics sets up additional biomanufacturing unit

PX’Therapeutics sets up additional biomanufacturing unit

Phase IIb/III clinical trial results of CINQUIL for pediatric EoE announced

Phase IIb/III clinical trial results of CINQUIL for pediatric EoE announced

MMR Information Systems to add new feature in its personal health record website

MMR Information Systems to add new feature in its personal health record website

Scientists discover new potential target for treating non-Hodgkin's lymphoma

Scientists discover new potential target for treating non-Hodgkin's lymphoma

Cancer pain drug market to be $3.7 billion in 2018

Cancer pain drug market to be $3.7 billion in 2018

YM BioSciences presents preclinical results of its small molecule VDA at the AACR-NCI-EORTC conference

YM BioSciences presents preclinical results of its small molecule VDA at the AACR-NCI-EORTC conference

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.